article
2 May 2014 | By Isabella Gashaw (Bayer HealthCare Pharmaceuticals), Karl Ziegelbauer (Bayer HealthCare Pharmaceuticals), Khusru Asadullah (Bayer HealthCare Pharmaceuticals), Martin Bechem (Bayer HealthCare Pharmaceuticals)
Preclinical drug target validation has the aim to increase confidence in a particular drug target. The process proves the initial hypothesis that a particular molecular target is key or even causative for pathogenic or symptomatic mechanisms in a disease. Several success factors seem to be of particular importance for the…